Treatment of a Large Cohort of Childhood Chronic Noninfectious Uveitis in a Multicentric Large Study: Adalimumab Versus Methotrexate as First‐Line Therapy
Main finding · Remission with first-line therapyResult — go to the resultχ2 31.35Authors' conclusion
Adalimumab shows promise as a potential first-line therapy for cCIU, particularly for posterior segment uveitis. Although effective in anterior uveitis, methotrexate leads children to relapse earlier than adalimumab.
Study context
- Population
- Children with chronic idiopathic uveitis (childhood chronic idiopathic uveitis (cCIU)) who received at least one systemic treatment; rheumatology and ophthalmology units, Florence, Italy, and Bristol, UK
- Participants
- 116 children
- Exposure
- Adalimumab vs methotrexate alone as first-line therapy
- Outcome
- Remission with first-line therapy (SUN criteria)
Methodological detailsmulticentre
- Multicentre
Main finding
Remission with first-line therapy
χ2
31.35
P < 0.001
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | χ2 | P value |
|---|---|---|
| Relapse with first-line therapyMethotrexate vs Adalimumab · methotrexate relapsed earlier | 4.35 | P = 0.043 |
| Stopping treatment for remissionAdalimumab vs Methotrexate · adalimumab more likely to stop for remission | 25.9 | P < 0.001 |
| Remission with second-line therapy (60 children; 45 adalimumab, 14 mycophenolate, 1 tocilizumab)Adalimumab vs Mycophenolate · adalimumab (± methotrexate) more likely to achieve remission | 14.66 | P = 0.005 |
| Remission with first-line therapy, nonanterior uveitis (subgroup)Adalimumab vs Methotrexate · not seen in the other children | 32.3 | P < 0.001 |
| Stopping first-line treatment due to persistent remission, nonanterior uveitis (subgroup)Adalimumab vs Methotrexate · not in anterior uveitis | 18.56 | P = 0.001 |
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Treatment of a Large Cohort of Childhood Chronic Noninfectious Uveitis in a Multicentric Large Study: Adalimumab Versus Methotrexate as First‐Line Therapy. Arthritis Rheumatol. Published 12 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →